AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoban, D. J.
Right arrow Articles by The Gemifloxacin Surveillance Study Research Group,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoban, D. J.
Right arrow Articles by The Gemifloxacin Surveillance Study Research Group,

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2000, p. 3008-3011, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

A Comparative In Vitro Surveillance Study of Gemifloxacin Activities against 2,632 Recent Streptococcus pneumoniae Isolates from across Europe, North America, and South America

D. J. Hoban,1,* S. K. Bouchillon,1 J. A. Karlowsky,1 J. L. Johnson,1 D. L. Butler,2 L. A. Miller,2 J. A. Poupard,2 and The Gemifloxacin Surveillance Study Research Group

Laboratories International for Microbiology Studies, Rolling Meadows, Illinois,1 and Department of Anti-Infectives, Research and Development, SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania2

Received 12 May 2000/Returned for modification 13 June 2000/Accepted 5 August 2000

From 1997 to 1999, 94 study centers in 15 European, 3 North American, and 2 South American countries contributed 2,632 isolates of Streptococcus pneumoniae to an international antimicrobial susceptibility testing study. Only 62.0% of isolates were susceptible to penicillin, while 22.3% were penicillin intermediate and 15.6% were penicillin resistant. Resistance to trimethoprim-sulfamethoxazole (24.4%), azithromycin (26.0%), and clarithromycin (27.1%) was also highly prevalent. For the penicillin-resistant isolates (n = 411), the MICs at which 90% of isolates are inhibited (MIC90s) for gemifloxacin, levofloxacin, ofloxacin, clarithromycin, and azithromycin were 0.03, 1, 2, >16, and >64 µg/ml, respectively. Similarly, for isolates resistant to both azithromycin and clarithromycin (n = 649), gemifloxacin, levofloxacin, ofloxacin, and penicillin MIC90s were 0.03, 1, 2, and 4 µg/ml, respectively. Overall rates of resistance to trovafloxacin (0.3%), levofloxacin (0.3%), grepafloxacin (0.6%), and ofloxacin (0.7%) were low. For ofloxacin-intermediate and -resistant isolates (n = 142), gemifloxacin had the lowest MIC90 (0.12 µg/ml) compared to the MIC90s of trovafloxacin (0.5 µg/ml), grepafloxacin (1 µg/ml), and levofloxacin (2 µg/ml). For all S. pneumoniae isolates tested, gemifloxacin MICs were <= 0.5 µg/ml, suggesting that gemifloxacin has the potential to be used as a treatment for pneumococcal infections, including those arising from isolates resistant to beta -lactams and macrolides.

* Corresponding author. Mailing address: International Health Management Associates, Inc., West Meadows Business Park, 1675 Winnetka Circle, Rolling Meadows, IL 60008. Phone: (847) 577-9135. Fax: (847) 577-7192. E-mail: dhoban{at}ihmainc.com.

Antimicrobial Agents and Chemotherapy, November 2000, p. 3008-3011, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.